Halozyme Therapeutics, Inc. $HALO Position Lifted by Arbejdsmarkedets Tillaegspension

Arbejdsmarkedets Tillaegspension boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.6% during the first quarter, Holdings Channel reports. The institutional investor owned 408,391 shares of the biopharmaceutical company’s stock after buying an additional 32,458 shares during the period. Halozyme Therapeutics makes up 0.7% of Arbejdsmarkedets Tillaegspension’s portfolio, making the stock its 6th biggest holding. Arbejdsmarkedets Tillaegspension’s holdings in Halozyme Therapeutics were worth $26,394,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares in the last quarter. Abel Hall LLC increased its holdings in Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 129 shares in the last quarter. StoneX Group Inc. increased its holdings in Halozyme Therapeutics by 3.8% in the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 132 shares in the last quarter. Moran Wealth Management LLC raised its position in Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 151 shares during the period. Finally, Coldstream Capital Management Inc. raised its position in Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 165 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the subject of several analyst reports. Morgan Stanley decreased their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. UBS Group reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $76.20 on Monday. Halozyme Therapeutics, Inc. has a one year low of $55.64 and a one year high of $82.26. The stock has a 50-day moving average price of $70.89 and a 200 day moving average price of $69.93. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company has a market capitalization of $9.04 billion, a P/E ratio of 27.41, a P/E/G ratio of 0.32 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $55,088,215. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,102 shares of company stock worth $5,205,798 over the last ninety days. 2.50% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.